Immune Response of Inactivated Rabies Vaccine Inoculated via Intraperitoneal, Intramuscular, Subcutaneous and Needle-Free Injection Technology-Based Intradermal Routes in Mice.
inoculation route
intradermal injection
intramuscular injection
intraperitoneal injection
needle-free injection technology
rabies vaccine
subcutaneous injection
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Sep 2023
02 Sep 2023
Historique:
received:
11
08
2023
revised:
24
08
2023
accepted:
25
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Inoculation routes may significantly affect vaccine performance due to the local microenvironment, antigen localization and presentation, and, therefore, final immune responses. In this study, we conducted a head-to-head comparison of immune response and safety of inactivated rabies vaccine inoculated via intraperitoneal (IP), intramuscular (IM), subcutaneous (SC) and needle-free injection technology-based intradermal (ID) routes in ICR mice. Immune response was assessed in terms of antigen-specific antibodies, antibody subtypes and neutralizing antibodies for up to 28 weeks. A live rabies virus challenge was also carried out to evaluate vaccine potency. The dynamics of inflammatory cell infiltration at the skin and muscle levels were determined via histopathological examination. The kinetics and distribution of a model antigen were also determined by using in vivo fluorescence imaging. Evidence is presented that the vaccine inoculated via the ID route resulted in the highest antigen-specific antibody and neutralizing antibody titers among all administration routes, while IP and IM routes were comparable, followed by the SC route. Antibody subtype analysis shows that the IP route elicited a Th1-biased immune response, while SC and IM administration elicited a prominent Th2-type immune response. Unexpectedly, the ID route leads to a balanced Th1 and Th2 immune response. In addition, the ID route conferred effective protection against lethal challenge with 40 LD50 of the rabies CVS strain, which was followed by IP and IM routes. Moreover, a one-third dose of the vaccine inoculated via the ID route provided comparable or higher efficacy to a full dose of the vaccine via the other three routes. The superior performance of ID inoculation over other routes is related to longer local retention at injection sites and higher lymphatic drainage. Histopathology examination reveals a transient inflammatory cell infiltration at ID and IM injection sites which peaked at 48 h and 24 h, respectively, after immunization, with all side effects disappearing within one week. These results suggest that needle-free injection technology-based ID inoculation is a promising strategy for rabies vaccination in regard to safety and efficacy.
Identifiants
pubmed: 37686393
pii: ijms241713587
doi: 10.3390/ijms241713587
pmc: PMC10488038
pii:
doi:
Substances chimiques
Rabies Vaccines
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Jilin Province Science and Technology Department
ID : 2018C004
Organisme : Jilin Province Science and Technology Department
ID : 20200708085YY
Références
J Med Virol. 1989 Feb;27(2):151-4
pubmed: 2522147
Expert Rev Vaccines. 2014 May;13(5):641-55
pubmed: 24655026
Adv Drug Deliv Rev. 2023 Aug;199:114949
pubmed: 37286086
J Neuroimmunol. 1992 Sep;40(1):81-7
pubmed: 1517399
J Am Assoc Lab Anim Sci. 2011 Sep;50(5):600-13
pubmed: 22330705
J Immunother. 2009 Feb-Mar;32(2):118-28
pubmed: 19238010
CSH Protoc. 2008 May 01;2008:pdb.prot4986
pubmed: 21356829
Acta Trop. 2000 Feb 25;75(1):39-52
pubmed: 10708006
Front Immunol. 2017 Jan 24;8:35
pubmed: 28167948
Sci Immunol. 2019 Mar 1;4(33):
pubmed: 30824527
Int J Nanomedicine. 2019 Dec 17;14:9917-9928
pubmed: 31908449
Vaccine. 2012 Oct 5;30(45):6427-35
pubmed: 22910287
PLoS Negl Trop Dis. 2018 Jun 6;12(6):e0006340
pubmed: 29874228
Nat Rev Immunol. 2004 Mar;4(3):211-22
pubmed: 15039758
J Infect Dis. 2015 Jun 15;211(12):1969-76
pubmed: 25567841
NPJ Vaccines. 2023 Apr 12;8(1):53
pubmed: 37045860
Hum Vaccin. 2011 Aug;7(8):811-27
pubmed: 21817854
Vaccine. 2008 Jul 23;26(31):3909-12
pubmed: 18547689
Vaccine. 2015 Aug 20;33(35):4238-46
pubmed: 25869890
Clin Exp Immunol. 1994 May;96(2):356-63
pubmed: 8187345
Med Microbiol Immunol. 2019 Apr;208(2):215-226
pubmed: 30707297
Clin Exp Immunol. 1986 Mar;63(3):491-7
pubmed: 3708902
JAMA. 1982 Feb 26;247(8):1138-42
pubmed: 7057603
Vaccine. 2017 Mar 27;35(14):1789-1796
pubmed: 28189403
Nat Med. 2010 Aug;16(8):915-20
pubmed: 20639891
J Infect Dis. 2015 May 1;211(9):1447-50
pubmed: 25391313
Vaccine. 1993;11(2):107-12
pubmed: 8438609
Neuropathology. 2014 Jun;34(3):277-83
pubmed: 24397792
Clin Vaccine Immunol. 2014 Aug;21(8):1023-36
pubmed: 24920599
Ther Deliv. 2015;6(9):1101-8
pubmed: 26458019
ACS Appl Bio Mater. 2021 Jul 19;4(7):5695-5706
pubmed: 35006739
Hum Vaccin Immunother. 2018 Mar 4;14(3):623-629
pubmed: 29400997
J Infect Dis. 2017 Jul 1;216(suppl_1):S161-S167
pubmed: 28838185
PLoS One. 2019 Feb 11;14(2):e0211896
pubmed: 30742635
Semin Cell Dev Biol. 2015 Feb;38:83-9
pubmed: 25534659
Life Sci. 2018 Aug 15;207:117-126
pubmed: 29859986
MMWR Morb Mortal Wkly Rep. 2019 May 24;68(20):458-462
pubmed: 31120868
Hum Vaccin Immunother. 2015;11(4):991-7
pubmed: 25745830
Expert Rev Vaccines. 2014 Mar;13(3):399-415
pubmed: 24512188
Virology. 1987 Nov;161(1):29-36
pubmed: 3672933
Am J Vet Res. 2003 Apr;64(4):491-8
pubmed: 12693542
Vaccine. 2018 Aug 9;36(33):5020-5029
pubmed: 30037417
Vaccine. 2014 Jul 23;32(34):4249-52
pubmed: 24930715
Hum Vaccin. 2010 Apr;6(4):346-54
pubmed: 20372053
PLoS Negl Trop Dis. 2015 Apr 16;9(4):e0003709
pubmed: 25881058
Drug Deliv Transl Res. 2011 Feb 1;1(1):7-12
pubmed: 21799951
Diabetes Technol Ther. 2016 Sep;18(9):525-31
pubmed: 27500713
Arch Virol. 2020 Mar;165(3):593-607
pubmed: 32016547
Annu Rev Immunol. 1989;7:145-73
pubmed: 2523712
Vaccine. 2016 Sep 14;34(40):4820-6
pubmed: 27554534
J Immunol. 2015 Nov 1;195(9):4358-68
pubmed: 26408670
Trop Med Infect Dis. 2017 Jul 21;2(3):
pubmed: 30270888
Lancet Infect Dis. 2016 Aug;16(8):915-22
pubmed: 27061887
Expert Rev Vaccines. 2008 Oct;7(8):1201-14
pubmed: 18844594
Vaccine. 2015 Jan 3;33(2):307-13
pubmed: 25448109
Vaccine. 2008 Jun 19;26(26):3197-208
pubmed: 18486285
BMC Infect Dis. 2019 Apr 11;19(1):321
pubmed: 30975098
Expert Rev Vaccines. 2017 Mar;16(3):273-287
pubmed: 27809689
Nat Rev Immunol. 2014 Oct;14(10):667-85
pubmed: 25234148
World J Virol. 2016 May 12;5(2):85-6
pubmed: 27175354
J Infect Dis. 1987 Jul;156(1):50-5
pubmed: 3598225
Microbes Infect. 2010 Dec;12(14-15):1163-9
pubmed: 20713172
Int J STD AIDS. 2004 Jan;15(1):7-16
pubmed: 14769164